Advances in targeted therapy and immunotherapy for esophageal cancer.
Advances in targeted therapy and immunotherapy for esophageal cancer.
复制标题
DOI：
10.1097/cm9.0000000000002768
复制
发表时间：
2023-08-20
影响因子：
6.1
通讯作者：
中科院分区：
文献类型：
--
作者：
食管癌是消化系统最常见的侵袭性恶性肿瘤之一，流行形势严峻，预后差。EC的早期诊断率低，大多数EC患者在晚期被诊断。多种多模式治疗逐渐发展成为晚期EC的主要治疗方法，包括手术、化疗、放疗、靶向治疗和免疫治疗。靶向治疗和免疫治疗的出现大大提高了EC患者的生存率。本文综述了食管癌靶向治疗和免疫治疗的最新进展，讨论了相关药物的有效性和安全性，总结了相关重要临床试验，为食管癌的治疗策略提供参考。
Esophageal cancer (EC) is one of the most common aggressive malignant tumors in the digestive system with a severe epidemiological situation and poor prognosis. The early diagnostic rate of EC is low, and most EC patients are diagnosed at an advanced stage. Multiple multimodality treatments have gradually evolved into the main treatment for advanced EC, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. And the emergence of targeted therapy and immunotherapy has greatly improved the survival of EC patients. This review highlights the latest advances in targeted therapy and immunotherapy for EC, discusses the efficacy and safety of relevant drugs, summarizes related important clinical trials, and tries to provide references for therapeutic strategy of EC.
影响因子：
2.7
作者：
Triantafyllou, Tania;van der Sluis, Pieter;Skipworth, Richard;Wijnhoven, Bas P L
通讯作者：
Wijnhoven, Bas P L
影响因子：
4.3
作者：
Li S;Luk HY;Xia C;Chen Z;Chan PKS;Boon SS
通讯作者：
Boon SS
影响因子：
3.8
作者：
Moehler M;Gepfner-Tuma I;Maderer A;Thuss-Patience PC;Ruessel J;Hegewisch-Becker S;Wilke H;Al-Batran SE;Rafiyan MR;Weißinger F;Schmoll HJ;Kullmann F;von Weikersthal LF;Siveke JT;Weusmann J;Kanzler S;Schimanski CC;Otte M;Schollenberger L;Koenig J;Galle PR
通讯作者：
Galle PR